1 of 4 FEATURED COMPANIES F. Hoffmann-La Roche Ltd Galderma S.A. Glaxosmithkline Plc Johnson & Johnson Merck & Co., Inc. Pfizer Inc. MORE - Industry Insights by Facial Aesthetic Relaxant Drug (Botox, Dysport, and Others), By Skeletal ... Research and Markets, 1 week ago
Pigmented Villonodular Synovitis Pipeline Report 2016 - Therapeutic Review of F. Hoffmann-La Roche, Five Prime Therapeutics, Novartis & Plexxikon - Research and Markets - Benzinga.com, 4 days ago
Pemphigus Vulgaris - Pipeline Review, H1 2016 Featuring Almirall, Biogen, F. Hoffmann-La Roche, HanAll Biopharma, Immunomedics, Novartis & Principia Biopharma - Research and Markets - 4 Traders, 1 week ago
1 images for "f hoffmann la roche ltd"
nearly doubled in morning trade Monday, after the company announced a license deal with F. Hoffmann-La Roche Ltd. to for the development and commercialization of its treatment for eye disease. As part of the deal, Eleven will receive an upfront ...Singapore Star.com, 2 weeks ago
Key Companies discussed in Report are - Eli Lilly and Company Novartis AG F. Hoffmann-La Roche Ltd. Merck & Co., Inc. Amgen Inc. Sanofi GlaxoSmithKline Plc Pfizer Inc. Takeda Pharmaceutical Company Limited Allergan Plc Buy complete ...Before It's News, 3 weeks ago 2016 Osteopenia Clinical Trials Market Analysis Before It's News, 3 weeks ago
Data on Toxicology Discussed by Researchers at F. Hoffmann-La Roche (Immunogenicity, Inflammation, and Lipid Accumulation in Cynomolgus Monkeys...
Data on Toxicology Discussed by Researchers at F. Hoffmann-La Roche (Immunogenicity, Inflammation, and Lipid Accumulation in Cynomolgus Monkeys Infused with a Lipidated Tetranectin-ApoA-I Fusion Protein) By a News Reporter-Staff News Editor at Life ...4 Traders, 3 weeks ago
(MarketLine via COMTEX News Network) -- Eleven Biotherapeutics, Inc., a biopharmaceutical company, has entered into an exclusive license agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. relating to Eleven's Interleukin-6 (IL-6) ...PredictWallStreet, 1 week ago Eleven Biotherapeutics ( EBIO ) Stock Junction, 2 weeks ago Eleven Biotherapeutics (EBIO) Stock Spikes 80% After Roche Agreement Wall Street Pit, 2 weeks ago ELEVEN BIOTHERAPEUTICS, INC. FILES (8-K) Disclosing Other Events, Regulation FD Disclosure, Financial Statements and Exhibits Equities.com, 2 weeks ago
Roche's subsidiary Genentech and biopharmaceutical firm Epizyme will collaborate on a phase 1b clinical trial to evaluate the combination of tazemetostat and Tecentriq for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL). ...Pharmaceutical Business Review, 5 days ago
TechNavio - Infiniti Research Ltd. About the Infectious Disease Treatment Market in China Infectious diseases are caused by pathogenic microorganisms such as bacteria, parasites, fungi, or viruses. They can be transmitted from one person to ...MarketResearch.com, 1 week ago
Roche has reported positive results from the global, randomised, double-blind, placebo-controlled Phase III trial (GiACTA), which evaluated Actemra / RoActemra (tocilizumab) in people with giant cell arteritis (GCA). During GiACTA, the patient ...Drug Development Technology, 3 weeks ago
Roche has introduced the new CoaguChek INRange system self-testing device which helps patients to spend more time in therapeutic range with minimal training. The Bluetooth enabled PT/INR home health device allows remote care programmes for ...Medical Devices Business Review, 4 weeks ago
Roche's Gazyva drug demonstrated superior progression-free survival compared to Mabthera/Rituxan in people with previously untreated follicular lymphoma in the phase III Gallium study that met its primary endpoint early. Gazyva/Gazyvaro is an ...Pharmaceutical Business Review, 1 month ago
on your WebpageAdd Widget >Get your members hooked!